1.

Record Nr.

UNISA996205532103316

Titolo

Cardiac CT, PET and MR [[electronic resource] /] / edited by Vasken Dilsizian and Gerald M. Pohost ; foreword by Robert O. Bonow

Pubbl/distr/stampa

Malden, MA, : Blackwell Futura, 2006

ISBN

1-280-74814-1

9786610748143

0-470-98853-3

1-4051-7171-5

Descrizione fisica

1 online resource (274 p.)

Altri autori (Persone)

DilsizianVasken

PohostGerald M

Disciplina

616.120754

Soggetti

Cardiovascular system - Imaging

Cardiovascular system - Tomography

Cardiovascular system - Magnetic resonance imaging

Tomography, Emission

Lingua di pubblicazione

Inglese

Formato

Materiale a stampa

Livello bibliografico

Monografia

Note generali

Description based upon print version of record.

Nota di bibliografia

Includes bibliographical references and index.

Nota di contenuto

Cardiac CT, PET and MR; Contents; Contributors; Foreword; Part I: Instrumentation, imaging techniques, and protocols; 1. Positron emission tomography; 2. Cardiovascular magnetic resonance: Basic principles, methods and techniques; 3. Multidetector and electron-beam computed tomography of the heart; Part II: Clinical applications; 4. PET assessment of myocardial perfusion; 5. PET: Metabolism, innervation and receptors; 6. MR angiography: Coronaries and great vessels; 7. Cardiovascular magnetic resonance: Evaluation of myocardial function, perfusion and viability; 8. MSCT coronary imaging

9. Cardiac computed tomography: Evaluation of myocardial function, perfusion and viabilityPart III: Concurrent noninvasive assessment of coronary anatomy, physiology, and myocellular integrity; 10. PET and MRI in cardiac imaging; 11. PET and CT in cardiac imaging: Is a paradigm shift from SPECT to hybrid PET/CT inevitable?; Index

Sommario/riassunto

The standard procedure for defining the anatomic extent and severity of coronary artery disease is catheter-based selective coronary



angiography. While there are advantages to coronary angiography, it is invasive with some risk of complications and requires a brief period of hospitalization, making it relatively expensive. Cardiac CT, PET and MR is a complete technique-oriented reference, offering real alternatives to the "standard procedure". Non-invasive techniques of coronary artery lumen imaging, such as multislice computed tomography (MSCT) and magnetic resonance imaging (CMR

2.

Record Nr.

UNINA9910787308103321

Titolo

Maximizing the impact of the Cures Acceleration Network : accelerating the development of new drugs and diagnostics : workshop summary / / Steve Olson and Anne B. Claiborne, rapporteurs ; Forum on Drug Discovery, Development, and Translation, Board on Health Sciences Policy, Institute of Medicine of the National Academies

Pubbl/distr/stampa

Washington, District of Columbia : , : National Academies Press, , [2012]

©2012

ISBN

0-309-26119-8

0-309-26117-1

Descrizione fisica

1 online resource (132 p.)

Disciplina

615.1/9

Soggetti

Drug monitoring

Drug development - United States

Drugs - United States - Design

Pharmaceutical industry - United States - Quality control

Lingua di pubblicazione

Inglese

Formato

Materiale a stampa

Livello bibliografico

Monografia

Note generali

Description based upon print version of record.

Nota di bibliografia

Includes bibliographical references (pages 71).

Nota di contenuto

Introduction [The history and goals of CAN (Cures Acceleration Network)] -- Approaches to accelerating translational science -- Application of matching authority -- Application of flexible research authority -- Situating CAN within the drug development ecosystem -- Final reflections on ways to maximize the goals of CAN.



Sommario/riassunto

Advances in technologies and knowledge are creating new avenues for research and opportunities for the discovery and clinical development of innovative therapies and diagnostics. However, despite these opportunities, only a small fraction of investigational products are successfully developed into cures and therapies that can be accessed by patients. One response to the ever-widening gap between the number and promise of basic scientific discoveries and the translation of those discoveries into therapies is a renewed emphasis on collaborative approaches among federal agencies, academia, and industry, all directed at the advancement of the drug development enterprise. The newly developed Cures Acceleration Network (CAN)-a part of the National Center for Advancing Translational Sciences (NCATS) within the National Institutes of Health (NIH)-has the potential to catalyze widespread changes in NCATS, NIH, and the drug development ecosystem in general. On June 4-5, 2012, the IOM Forum on Drug Discovery, Development, and Translation held, at the request of NCATS, a workshop-bringing together members of federal government agencies, the private sector, academia, and advocacy groups-to explore options and opportunities in the implementation of CAN. Accelerating the Development of New Drugs and Diagnostics: Maximizing the Impact of the Cures Acceleration Network: Workshop Summary summarizes the workshop."--Publisher's description.